We’re excited to share a major milestone: Thestra’s Eplin‑biomarker has been granted a European patent on 29.4.2026. This strengthens our scientific foundation and accelerates our mission to transform cancer diagnostics.
The patent protects Eplin’s unique biological role in assessing tumor aggressiveness — giving Thestra a clear competitive edge and long‑term exclusivity in this rapidly growing diagnostic area.
For our clinical and laboratory business partners, the patent provides confidence in a scientifically validated, IPR protected technology that supports novel risk‑stratified care pathways.
This milestone also advances the commercialization and regulatory progress of EPLINEX® method, reinforcing its differentiation under IVDR and increasing its value for international expansion.
A significant step toward more precise cancer diagnostics.